As Republicans work to reform Medicaid, they must contend with questions about the appropriate financial support level and the grant structure of the program, according to Gail Wilensky, PhD, of Project HOPE.
As Republicans work to reform Medicaid, they must contend with questions about the appropriate financial support level and the grant structure of the program, according to Gail Wilensky, PhD, of Project HOPE.
Transcript (slightly modified)
Medicaid has been a huge point of contention within the Republican Party. Do you think something will give?
I think there are 2 big questions about Medicaid. One is the financial support level. Are we talking about trying to extract, going forward, large sums of money? Are we talking about very modestly slowing the spend rate that we’ve seen on Medicaid? And the second is what should the structure be. I have much more sympathy with the move to a per capita block grant with some outcome metrics as a requirement, provided that the baseline makes sense and the rate of increase is appropriate for the different populations affected.
The reason I believe that is that we have seen in the past couple of decades most of the new money that has come in through Medicaid has been federal money, and much of the supposedly state match has been creative financing that just moves money around and then gives it back to the state. It has indicated some serious questions about the viability and validity of a matching grant in Medicaid. I think that continues to exist.
So, the structure is one thing. It’s now our only open-ended entitlement program left in the United States. Medicare, because of the IPAB structure, actually has a limit in place. I think questioning that is one idea. It is having a base structure and a growth rate that is appropriate, that is a whole different level of debate. People unfortunately are mixing the two up.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More